Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.
Fulgent Genetics (NASDAQ:FLGT) used its fourth-quarter and full-year 2025 earnings call to outline continued growth in its laboratory services business, accelerating investments in digital pathology ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する